JP2021504414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504414A5 JP2021504414A5 JP2020529467A JP2020529467A JP2021504414A5 JP 2021504414 A5 JP2021504414 A5 JP 2021504414A5 JP 2020529467 A JP2020529467 A JP 2020529467A JP 2020529467 A JP2020529467 A JP 2020529467A JP 2021504414 A5 JP2021504414 A5 JP 2021504414A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- antibody
- antigen
- disorder
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JOZQZYKBYAUYOK-UHFFFAOYSA-N CC(C)C(CO1)OC1=O Chemical compound CC(C)C(CO1)OC1=O JOZQZYKBYAUYOK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592169P | 2017-11-29 | 2017-11-29 | |
| US62/592,169 | 2017-11-29 | ||
| PCT/US2018/063171 WO2019108860A1 (en) | 2017-11-29 | 2018-11-29 | Compositions and methods for the depletion of cd2+ cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504414A JP2021504414A (ja) | 2021-02-15 |
| JP2021504414A5 true JP2021504414A5 (https=) | 2022-01-11 |
Family
ID=66664617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529467A Pending JP2021504414A (ja) | 2017-11-29 | 2018-11-29 | Ｃｄ２＋細胞の枯渇のための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200368363A1 (https=) |
| EP (1) | EP3717519A4 (https=) |
| JP (1) | JP2021504414A (https=) |
| KR (1) | KR20200090801A (https=) |
| CN (1) | CN111670200A (https=) |
| AU (1) | AU2018374282A1 (https=) |
| BR (1) | BR112020010816A2 (https=) |
| CA (1) | CA3082166A1 (https=) |
| CO (1) | CO2020006855A2 (https=) |
| EA (1) | EA202090922A1 (https=) |
| IL (1) | IL274817A (https=) |
| MX (1) | MX2020004806A (https=) |
| SG (1) | SG11202004192XA (https=) |
| WO (1) | WO2019108860A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| WO2021259927A2 (en) * | 2020-06-23 | 2021-12-30 | Zelarion Malta Limited | Anti-cd2 antibodies |
| WO2022027052A1 (en) * | 2020-07-28 | 2022-02-03 | Northwestern University | Clotrimazole as a treatment for immunodeficiency disorders |
| JP2025517363A (ja) * | 2022-05-17 | 2025-06-05 | ザ ユーエービー リサーチ ファンデーション | 炎症性皮膚障害を治療または予防するための方法及び組成物 |
| WO2024079046A1 (en) * | 2022-10-10 | 2024-04-18 | Zelarion Malta Limited | Anti-cd2 antibodies for type 1 diabetes |
| WO2024118559A2 (en) * | 2022-11-28 | 2024-06-06 | Icell Gene Therapeutics Inc. | Engineered immune cells for treating disorders, compositions and methods thereof |
| TW202535955A (zh) * | 2023-11-27 | 2025-09-16 | 丹麥商珍美寶股份有限公司 | 用於ｐｔｋ７檢測之抗體及方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69428272T2 (de) * | 1993-03-05 | 2002-06-27 | Universite Catholique De Louvain, Louvair La Neuve | Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum |
| US7592006B1 (en) * | 1993-03-05 | 2009-09-22 | Université Catholique de Louvain | Composition comprising the LO-CD2a antibody |
| US5795572A (en) * | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
| US6849258B1 (en) * | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| JP4808841B2 (ja) * | 1997-07-18 | 2011-11-02 | バイオトランスプラント，インコーポレイテッド | Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法 |
| US6558662B2 (en) * | 1997-11-14 | 2003-05-06 | The General Hospital Corporation | Treatment of hematologic disorders |
| SI1545613T1 (sl) * | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| WO2004022097A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| CN105377304B (zh) * | 2014-03-10 | 2018-05-15 | 海德堡医药有限责任公司 | 鹅膏毒肽衍生物 |
| EP3212668B1 (en) * | 2014-10-31 | 2020-10-14 | AbbVie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| WO2015151079A2 (en) * | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| SG11202110287QA (en) * | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
-
2018
- 2018-11-29 EA EA202090922A patent/EA202090922A1/ru unknown
- 2018-11-29 KR KR1020207016423A patent/KR20200090801A/ko not_active Ceased
- 2018-11-29 JP JP2020529467A patent/JP2021504414A/ja active Pending
- 2018-11-29 MX MX2020004806A patent/MX2020004806A/es unknown
- 2018-11-29 CN CN201880088127.XA patent/CN111670200A/zh active Pending
- 2018-11-29 US US16/768,036 patent/US20200368363A1/en not_active Abandoned
- 2018-11-29 EP EP18883544.1A patent/EP3717519A4/en not_active Withdrawn
- 2018-11-29 BR BR112020010816-2A patent/BR112020010816A2/pt not_active IP Right Cessation
- 2018-11-29 WO PCT/US2018/063171 patent/WO2019108860A1/en not_active Ceased
- 2018-11-29 CA CA3082166A patent/CA3082166A1/en active Pending
- 2018-11-29 AU AU2018374282A patent/AU2018374282A1/en not_active Abandoned
- 2018-11-29 SG SG11202004192XA patent/SG11202004192XA/en unknown
-
2020
- 2020-05-20 IL IL274817A patent/IL274817A/en unknown
- 2020-06-03 CO CONC2020/0006855A patent/CO2020006855A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504414A5 (https=) | ||
| JP2019522050A5 (https=) | ||
| WO2019108863A4 (en) | Compositions and methods for the depletion of cd5+ cells | |
| DK1507556T3 (en) | Calicheamicin derivative-carrier conjugates | |
| WO2019108860A4 (en) | Compositions and methods for the depletion of cd2+ cells | |
| JP2021500391A5 (https=) | ||
| DiJoseph et al. | Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
| WO2018210795A1 (en) | ANTI-SIRPα ANTIBODIES | |
| RU2018130757A (ru) | Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74 | |
| CA2153692A1 (en) | Recombinant anti-vla4 antibody molecules | |
| RU2010133892A (ru) | Гуманизированные моноклональные антитела против человеческого nkg2a | |
| HRP20240939T1 (hr) | Anti-cd3 protutijela i metode uporabe | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2006506955A5 (https=) | ||
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| JP2016503067A5 (https=) | ||
| WO2013072523A4 (en) | Bi-specific antibodies for medical use | |
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| WO2022268050A1 (zh) | 一种药物组合及其用途 | |
| JP2026021532A (ja) | Ｂｔｌａ抗体 | |
| WO2008081331A2 (en) | Enhancing the level of antibody expression by framework re-engineering | |
| JPWO2021202770A5 (https=) |